chartexchange

ArriVent BioPharma Reports Third Quarter 2026 Financial Results

GlobeNewswire Inc. | Nov 9, 2026 4:01 PM EST

NEWTOWN SQUARE, Pa., Nov. 09, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results for the third quarter ended September 30, 2026, and highlighted recent Company progress.

Read original article